JLE

European Cytokine Network

MENU

Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemotherapy Volume 12, numéro 4, December 2001

Auteurs
Institute of Highly Pure Biopreparations, Pudozhskaya St., 7, St. Petersburg, 197110, Russia.
  • Page(s) : 664-70
  • Année de parution : 2002

INTRODUCTION The limiting toxicity of the majority of cytostatic drugs used in the chemotherapy of malignant tumors reveals itself as development of myelodepression, primarily leukopenia, caused by a decrease in the neutrophil count. Toxic myelodepression impedes the continuation chemotherapy at the necessary intensity and intervals planned, with the result that the therapeutic effect is reduced. Several growth factors (different colony-stimulating [...]